Cargando…
Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in chi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society for Pediatric Endocrinology
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687628/ https://www.ncbi.nlm.nih.gov/pubmed/23926385 http://dx.doi.org/10.1297/cpe.19.101 |
_version_ | 1782273961657106432 |
---|---|
author | Matsushita, Rie Nakagawa, Yuichi Nagata, Eiko Satake, Eiichiro Sano, Shinichiro Yamaguchi, Rie Fujisawa, Yasuko Masui, Ayako Nakanishi, Toshiki Endo, Akira Kagawa, Jiro Ohzeki, Takehiko |
author_facet | Matsushita, Rie Nakagawa, Yuichi Nagata, Eiko Satake, Eiichiro Sano, Shinichiro Yamaguchi, Rie Fujisawa, Yasuko Masui, Ayako Nakanishi, Toshiki Endo, Akira Kagawa, Jiro Ohzeki, Takehiko |
author_sort | Matsushita, Rie |
collection | PubMed |
description | Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in children. We retrospectively compared the efficacy of different doses of MMI in 35 children with GD. Eight children were excluded due to lack of follow-up, etc. The remaining 27 children were divided into a high-dose group (HD; MMI≥0.7 (0.85 ± 0.13) mg/kg/d, n=8) and a low-dose group (LD; MMI<0.7 (0.51 ± 0.12) mg/kg/d, n=19), and we compared the time needed for the serum FT4 levels to normalize (≤1.6 ng/dl) between the groups. There were no significant differences between the FT4 levels (HD: 5.5 ± 2.8 ng/dl; LD: 5.0 ± 2.4 ng/dl p=0.59) or thyroid stimulating hormone receptor antibody levels (HD: 56.2 ± 29.3%; LD: 60.9 ± 27.2% p=0.69) between the groups before treatment. The mean time required to normalize the FT4 levels was 22.5 ± 7.4 d in the HD group and 28.8 ± 16.2 d in the LD group (p=0.30). In addition, no other factor influenced the time to efficacy of MMI. A dose of MMI<0.7 (0.51 ± 0.12) mg/kg/d appears to as effective as a higher dose in normalizing the serum FT4 level in children with mild or moderate GD. |
format | Online Article Text |
id | pubmed-3687628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The Japanese Society for Pediatric Endocrinology |
record_format | MEDLINE/PubMed |
spelling | pubmed-36876282013-08-07 Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study Matsushita, Rie Nakagawa, Yuichi Nagata, Eiko Satake, Eiichiro Sano, Shinichiro Yamaguchi, Rie Fujisawa, Yasuko Masui, Ayako Nakanishi, Toshiki Endo, Akira Kagawa, Jiro Ohzeki, Takehiko Clin Pediatr Endocrinol Original Article Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in children. We retrospectively compared the efficacy of different doses of MMI in 35 children with GD. Eight children were excluded due to lack of follow-up, etc. The remaining 27 children were divided into a high-dose group (HD; MMI≥0.7 (0.85 ± 0.13) mg/kg/d, n=8) and a low-dose group (LD; MMI<0.7 (0.51 ± 0.12) mg/kg/d, n=19), and we compared the time needed for the serum FT4 levels to normalize (≤1.6 ng/dl) between the groups. There were no significant differences between the FT4 levels (HD: 5.5 ± 2.8 ng/dl; LD: 5.0 ± 2.4 ng/dl p=0.59) or thyroid stimulating hormone receptor antibody levels (HD: 56.2 ± 29.3%; LD: 60.9 ± 27.2% p=0.69) between the groups before treatment. The mean time required to normalize the FT4 levels was 22.5 ± 7.4 d in the HD group and 28.8 ± 16.2 d in the LD group (p=0.30). In addition, no other factor influenced the time to efficacy of MMI. A dose of MMI<0.7 (0.51 ± 0.12) mg/kg/d appears to as effective as a higher dose in normalizing the serum FT4 level in children with mild or moderate GD. The Japanese Society for Pediatric Endocrinology 2010-12-29 2010-10 /pmc/articles/PMC3687628/ /pubmed/23926385 http://dx.doi.org/10.1297/cpe.19.101 Text en 2010©The Japanese Society for Pediatric Endocrinology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. |
spellingShingle | Original Article Matsushita, Rie Nakagawa, Yuichi Nagata, Eiko Satake, Eiichiro Sano, Shinichiro Yamaguchi, Rie Fujisawa, Yasuko Masui, Ayako Nakanishi, Toshiki Endo, Akira Kagawa, Jiro Ohzeki, Takehiko Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study |
title | Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study |
title_full | Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study |
title_fullStr | Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study |
title_full_unstemmed | Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study |
title_short | Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up
Study |
title_sort | initial treatment of pediatric graves’ disease with methimazole: a retrospective follow-up
study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687628/ https://www.ncbi.nlm.nih.gov/pubmed/23926385 http://dx.doi.org/10.1297/cpe.19.101 |
work_keys_str_mv | AT matsushitarie initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT nakagawayuichi initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT nagataeiko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT satakeeiichiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT sanoshinichiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT yamaguchirie initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT fujisawayasuko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT masuiayako initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT nakanishitoshiki initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT endoakira initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT kagawajiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy AT ohzekitakehiko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy |